רופרון -אי 9 מ.י./0.5 מ"ל

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

INTERFERON ALFA 2A 9 MIU / 0.5 ML

Disponible depuis:

ROCHE PHARMACEUTICALS (ISRAEL) LTD

Code ATC:

L03AB04

forme pharmaceutique:

SOLUTION FOR INJECTION

Mode d'administration:

S.C

Fabriqué par:

HOFFMANN LA ROCHE, SWITZERLAND

Groupe thérapeutique:

INTERFERON ALFA-2A

indications thérapeutiques:

Roferon-A is indicated for the treatment of:- Condylomata acuminata - Hairy cell leukaemia.- AIDS patients with progressive, asymptomatic Kaposi's sarcoma who have a CD4 count > 250/mm3.- Chronic phase Philadelphia-chromosome positive chronic myelogenous leukaemia. Roferon-A is not an alternative treatment for CML patients who have an HLA-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. It is still unknown whether Roferon-A can be considered as a treatment with a curative potential in this indication.- Adult patients with histologically proven chronic hepatitis B who have markers for viral replication, i.e., those who are positive for HBV DNA or HBeAg.- Adult patients with histologically proven chronic hepatitis C who are positive for HCV antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation.- Follicular non-Hodgkin’s lymphoma.- Advanced renal cell carcinoma.- Patients with AJCC stage II m

Date de l'autorisation:

2012-12-01